Long non-coding RNA, HOTAIRM1, promotes glioma malignancy by forming a ceRNA network

Abstract

Long non-coding RNAs play critical roles in tumorigenesis and the immune process. In this study, RNA sequencing data for 946 glioma samples from The Cancer Genome Atlas and the Chinese Glioma Genome Atlas databases were analyzed to evaluate the prognostic value and function of homeobox A transcript antisense RNA myeloid-specific (HOTAIRM)1. HOTAIRM1 expression was associated with clinical and molecular features of glioma: patients with high HOTAIRM1 expression were more likely to be classified as malignant cases, and elevated HOTAIRM1 level was associated with shorter survival time in subgroups stratified by clinical and molecular features. A multivariate Cox regression analysis showed that HOTAIRM1 was an independent prognostic factor for patient outcome. In vitro experiments revealed that HOTAIRM1 knockdown suppressed the malignant behavior of glioma and increased tumor sensitivity to temozolomide. The results of an in silico analysis indicated that HOTAIRM1 promotes the malignancy of glioma by acting as a sponge for microRNA (miR)-129-5p and miR-495-3p. HOTAIRM1 overexpression was also associated with immune activation characterized by enhanced T cell-mediated immune and inflammatory responses. These results suggest that HOTAIRM1 is a prognostic biomarker and potential therapeutic target in glioma.

Profiling pro-neural to mesenchymal transition identifies a lncRNA signature in glioma

“…First, predicted binding of micro (mi)RNAs with the 10 lncRNAs were collected using the DIANA tools and LncBase Predicted v.2 ( https://www.microrna.gr/LncBase/ ). LncRNA/miRNA pairs and potential target genes of overlapping miRNAs were generated as described in our previous study [ 16 ]. Then, we identified miRNA-mRNA pairs by intersecting target genes with SRGs.…”

“…The RNA expressions of LINC01503, CD44, and OLIG2 were calculated by the 2 −ΔΔCt method and normalized to 18S mRNA expression. The procedure of protein isolation and western blotting was similar as that described in previous study [16]. The primary antibodies were as follows: CD44 (1:1000; Cell Signaling Technology, Boston, USA), OLIG2 (1:1000; Abcam, Cambridge, UK), β-actin (1:1000; Proteintech, Rosemont, IL, USA).…”

CeRNA Network Analysis Representing Characteristics of Different Tumor Environments Based on 1p/19q Codeletion in Oligodendrogliomas

“…In a glioma study, they report on the oncogenic role of maternally expressed 3 (MEG3) as a tumor suppressor lncRNA that is downregulated in gliomas [34] and nuclear paraspeckle assembly transcript 1 (NEAT1) on by competing for miR-let-7e and modulating the expression of signal transducer and activator of transcription 3 (STAT3) and NRAS proto-oncogene, GTPase (NRAS) [34,35]. The functions of lncRNAs as biomarkers and therapeutic targets in glioma are well reported [36][37][38]; Collectively, these findings showed that the interactions among lncRNAs, mRNA, and miRNA in ceRNA network implicate a potential role as tumor suppressive or oncogenic effects. However, data regarding their effects on OD and the 1p/19q codeletion remain limited.…”

Long non-coding RNA NCK1-AS1 promotes the tumorigenesis of glioma through sponging microRNA-138-2-3p and activating the TRIM24/Wnt/β-catenin axis

“…Importantly, a competing endogenous RNA (ceRNA) theory proposed recently, which suggests that non-coding RNAs and protein-coding RNAs work as ceRNAs through competing for miRNAs via shared miRNA recognition elements [14,15], has aroused wide concerns. Several ceRNA networks have been validated to play key functions in metastasis, proliferation, and apoptosis in human glioma cells [16,17]. The possible ceRNA networks in glioma and the mechanisms involved remain largely unknown.…”